Samsung BioLogics’ stock slides after regulators claim accounting rules infraction

2nd May 2018 Uncategorised 0

Contract drug manufacturing giant Samsung BioLogics saw its stock slide, losing almost $6 billion in market value Wednesday, after South Korean securities regulators said the company broke accounting rules.

More: Samsung BioLogics’ stock slides after regulators claim accounting rules infraction
Source: fierce